then click 'INVEST NOW' to place your bid
AusBiz: a taste for psychedelics
Why Silicon Valley is turning to Magic Mushrooms
Johns Hopkins Opens New Center for Psychedelic Research
Will magic mushrooms be the cure for the $300 billion mental health market?
GreenStar Biosciences - Psychedelics and the $180 billion dollar mental health problem
60 minutes: Revolutionary drug trial could see ecstasy used asprescription medicine for those living with PTSD and mental illness
Shroom Boom: A Growing Investment Trend in Psychedelic Medicine
CoPeak Corporate Pty Ltd ACN 632 277 144 is the trustee for Peak Asset Management Unit Trust (“Peak”) and is a corporate authorised representative (#1249050) of Equity Underwriters Pty Ltd (AFSL #244040).
Peak accepts no responsibility for any views expressed and marketing material contained in this email except where the message specifically states otherwise. Information provided in this email is general information only, is not intended to be comprehensive and complete and does take into account your objectives, financial situation or needs. No person named in this email guarantees the performance of GreenStar and its subsidiaries or any return on investment made pursuant to the Placement.
Before acting on the information contained in this email, Peak recommends that you consider whether it is appropriate for your circumstances and where appropriate, seek obtain professional investment advice.
This email contains forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this email, are expected to take place. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other important factors.
No person named in this email guarantees or give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this email and the information (including any attachments) contained herein will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.
If this email contains reference to any financial products, you should obtain the current Product Disclosure Statement (PDS) or other disclosure documents for the particular products and consider this information before making any decisions regarding the products. The Financial Services Guide (FSG) can be found at www.peakassetmanagement.com.au or by telephoning Peak on 1300 304 460.